Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02728726 · ClinicalTrials.gov registry record · Phase 4
Sugammadex vs Placebo to Prevent Residual Neuromuscular Block
A Phase 4 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 4
- Development phase
- 260
- Enrollment target
NCT02728726: Completed Phase 4 study, sponsored by Mayo Clinic.
NCT02728726 is a Phase 4 study that has completed, run by Mayo Clinic. The registered enrollment target is 260 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02728726, a Phase 4 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 260 participants
- Enrollment target
Study Summary
The study is designed to determine whether patients who receive sugammadex immediately after tracheal extubation will exhibit a decrease in the incidence of postoperative residual paralysis and an associated decrease in the incidence of postoperative respiratory depression.
Interventions
- DRUG Placebo
- DRUG Sugammadex
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 260 participants |
| Start Date | 2016-06 |
| Est. Completion | 2019-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02728726
The ClinicalTrials.gov registry entry for NCT02728726 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 260 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02728726 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02728726 about?
NCT02728726 is a clinical study titled "Sugammadex vs Placebo to Prevent Residual Neuromuscular Block". The study is designed to determine whether patients who receive sugammadex immediately after tracheal extubation will exhibit a decrease in the incidence of postoperative residual paralysis and an associated decrease in the incidence of postoperative respiratory depression.
What is the current status of trial NCT02728726?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 260 participants. The study started on 2016-06. Estimated completion is 2019-12.
What interventions are being tested in trial NCT02728726?
The interventions under investigation include: Placebo (DRUG), Sugammadex (DRUG).
Who is sponsoring clinical trial NCT02728726?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.